

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with MarryAnne Armstrong on February 04, 2010.

IN THE CLAIMS –

Please **REPLACE** claims on date 11/24/2009 to the following claims:


Application/Control Number: 10/568,148

Page 3

Art Unit: 1625

“

1. (Previously presented) A quinuclidine derivative represented by Formula II



wherein

----- represents an optional double bond;

n is 1, 2 or 3;

X represents a linker selected from -O-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-,  
-C(=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -C(=O)-, -C(=S)-,



Y represents O, S, SO<sub>2</sub>, or NR', wherein R' represents hydrogen or alkyl.

2. (Original) The quinuclidine derivative of claim 1, wherein ----- represents a single (covalent) bond.

3. (Previously presented) The quinuclidine derivative of claim 1, wherein n is 1, 2 or 3.

4. (Previously presented) The quinuclidine derivative of claim 1, wherein X represents a linker selected from -O-, -S-, and -CH<sub>2</sub>-.

5. (Previously presented) The quinuclidine derivative of claim 1, wherein Y represents O, S, SO<sub>2</sub>, or NR', wherein R' represents hydrogen or alkyl.

6. (Original) The quinuclidine derivative of claim 5, which is  
(±)-3-(Dibenzofuran-2-yloxy)-1-azabicyclo[2.2.2]octane;  
or an enantiomer thereof, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof.

7. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a quinuclidine derivative of claim 1, or a pharmaceutically-acceptable addition salt thereof.

8.-16. (Canceled)

17. (Canceled)

”

***Allowable Subject Matter***

Claims 1-7 are allowed.

The following is an examiner's statement of reasons for allowance:

Claims 1-7 were rejected under Obvious Double Patenting over ap # 10/772,192 in the previous office action and the rejection is withdrawn in light of applicant's amendment argument in the paper dated on 11/24/2009.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR

Art Unit: 1625

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/NILOOFAR RAHMANI/

02/04/2010

/D. Margaret Seaman/

Primary Examiner, Art Unit 1625